Climb Bio (CLYM) Change in Accured Expenses (2020 - 2026)

Climb Bio (CLYM) has 7 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 175.28% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (down 175.62% YoY) and the FY2025 annual result came in at $372000.0, down 74.26% from the prior year.
• Change in Accured Expenses fell to -$1.5 million in Q1 2026, from $220000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q1 2025 to a low of -$1.7 million in Q3 2022.
• A 5-year average of -$111941.2 and a median of $95000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 373.15% in 2025, down 933.68% in 2025.
• Tracing CLYM's Change in Accured Expenses over 5 years: stood at $613000.0 in 2022, then grew by 9.3% to $670000.0 in 2023, then soared by 52.84% to $1.0 million in 2024, then slumped by 78.52% to $220000.0 in 2025, then slumped by 796.36% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $220000.0 (Q4 2025), and -$792000.0 (Q3 2025), per Business Quant data.